David Templeton
Vermogen: - $ op 30-06-2026
Vermogen: - $ op 30-06-2026
Dr. David Templeton was previously employed as an Executive Director & Technical Director by N4 Pharma Plc, a Director-Clinical Pharmacology by Eisai Ltd. (United Kingdom), a Head-Non Clinical Development by Celltech Ltd., and a Head-Biometrics by Merck Generics Ltd.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 31-12-2024 | 0 ( -.--% ) | - $ | 30-06-2026 |
| Bedrijven | Functie | Einde |
|---|---|---|
| THALIA THERAPEUTICS PLC | Voorzitter | 21-05-2019 |
Eisai Ltd. (United Kingdom)
Eisai Ltd. (United Kingdom) Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Corporate Officer/Principal | 01-01-2010 |
Celltech Ltd.
Celltech Ltd. Miscellaneous Commercial ServicesCommercial Services Provides research and development on natural science and engineering | Corporate Officer/Principal | 01-01-2004 |
Merck Generics Ltd.
Merck Generics Ltd. Pharmaceuticals: MajorHealth Technology Provides therapies and drugs products | Corporate Officer/Principal | - |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 4 |
|---|---|
Eisai Ltd. (United Kingdom)
Eisai Ltd. (United Kingdom) Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Health Technology |
Celltech Ltd.
Celltech Ltd. Miscellaneous Commercial ServicesCommercial Services Provides research and development on natural science and engineering | Commercial Services |
N4 Pharma Plc
N4 Pharma Plc BiotechnologyHealth Technology Provides specialist pharmaceutical services that reformulates existing drugs and vaccines to improve their performance | Health Technology |
Merck Generics Ltd.
Merck Generics Ltd. Pharmaceuticals: MajorHealth Technology Provides therapies and drugs products | Health Technology |
Kies jouw editie
Alle financiële informatie op nationaal niveau